Ovaric acid: latest news - GoINPHARMA
Saturday, 15 December 2018 - 21:47

Ovaric acid

Investors reward Intercept Pharmaceuticals again

Intercept Pharmaceuticals is apparently experiencing a positive momentum, following the hardship over the last 8 months, which had caused shares to drop–they have fallen approximately 50% starting from September 2017. The positive phase reflects the New York-based company issuing new…

FDA issues warning about Intercept’s Ocaliva after 19 patients died

The FDA has officially warned doctors about the risks from Intercept Pharmaceuticals’ Ocaliva (obeticholic acid), after 19 patients on Intercept’s drug, developed to treat PBC (Primary Biliary Cholangitis) had died. The FDA, anyway, has specified that the deaths have occurred…

The European Commission approves Intercept’s Ocaliva

Intercept Pharmaceuticals, a biopharmaceutical company focused on the development and commercialization of therapeutics to treat progressive non-viral liver diseases, announced that the European Commission has granted conditional approval for Ocaliva (obeticholic acid) for the treatment of primary biliary cholangitis (PBC)…